Monitor closing conditions and timing of ETICOVO U.S. launch. The deal adds two approved biosimilars to Teva's immunology portfolio, but revenue contribution depends on market uptake and competition from originators and other biosimilars.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 3 $41.91entry
- T+1 · yesterday −0.14%α −1.79% · $41.85
- T+2 · todayOpen
- T+5 · in 5d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Teva announced a license and commercialization agreement with Samsung Bioepis for two FDA-approved immunology biosimilars: ETICOVO (etanercept-ykro, biosimilar to Enbrel) and infliximab-abda (biosimilar to Remicade). Teva will obtain U.S. commercialization rights for ETICOVO upon closing (expected by end of 2026) and for infliximab-abda in Q3 2027. The deal expands Teva's biosimilar portfolio under its Pivot to Growth strategy, with an upfront payment over 3 years, potential launch and sales milestones, and profit sharing.
Key Facts
- Teva obtains U.S. commercialization rights for two FDA-approved immunology biosimilars: ETICOVO (etanercept-ykro) and infliximab-abda.
- ETICOVO rights transfer at closing (expected by end of 2026); infliximab-abda rights transfer in Q3 2027.
- Samsung Bioepis remains responsible for regulatory oversight and manufacturing of both products.
- Teva will pay an upfront payment over 3 years; Samsung Bioepis eligible for additional launch and sales milestone payments.
- Teva and Samsung Bioepis will share profit from commercialization.
- Infliximab-abda was FDA-approved in 2017; ETICOVO was FDA-approved in 2019 and is not currently available on the U.S. market.
- Deal builds on prior collaborations: EPYSQLI (eculizumab-aagh) in 2025, OPUVIZ (aflibercept) in Canada and a global agreement for up to six early-stage biosimilar candidates in 2026.
Financial Impact
Upfront payment over 3 years, plus potential launch and sales milestones; profit sharing on commercialization. Specific dollar amounts not disclosed.
Risk Factors
- Transaction subject to customary closing conditions and regulatory approvals; closing may be delayed or not occur.
- ETICOVO is not currently marketed in the U.S.; launch timing and commercial success are uncertain.
- Biosimilar market faces pricing pressure and competition from originator biologics and other biosimilars.
- Upfront payment and milestone obligations could impact cash flow; profit sharing reduces Teva's margin per product.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3393969 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Nov 5, 2026 today | 144 | $41.89 | awaiting T+20 | awaiting T+20 | $41.78 (−0.26%) |
Nov 4, 2026 1d ago | 144 | $41.85 | awaiting T+20 | awaiting T+20 | $41.78 (−0.17%) |
Nov 3, 2026 2d ago | 8-K | No price | awaiting T+20 | awaiting T+20 | No price |
Nov 3, 2026 2d ago | Press Release | $41.91 | awaiting T+20 | awaiting T+20 | $41.78 (−0.31%) |
Nov 3, 2026 2d ago | Press Release | $41.91 | awaiting T+20 | awaiting T+20 | $41.78 (−0.31%) |
Nov 2, 2026 3d ago | Press Release | $40.70 | awaiting T+20 | awaiting T+20 | $41.78 (−2.65%) |
Nov 2, 2026 3d ago | SC 13G/A | $40.70 | awaiting T+20 | awaiting T+20 | $41.78 (+2.65%) |
Oct 29, 2026 7d ago | 8-K | $42.09 | awaiting T+20 | awaiting T+20 | $41.78 (−0.74%) |
Oct 27, 2026 9d ago | Press Release | $40.39 | awaiting T+20 | awaiting T+20 | $41.78 (+3.44%) |
Oct 15, 2026 21d ago | Institutional Cluster | $41.11 | awaiting T+20 | awaiting T+20 | $41.78 (−1.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers